Ophthalmology

The dual Ang-2 and VEGF-A pathway inhibitor faricimab is noninferior to aflibercept for improving visual acuity in people with diabetic macular edema, and an individualized dosing strategy could help reduce treatment burden, suggest findings from the YOSEMITE and RHINE trials.

New users of SGLT2 inhibitors are more likely to develop retinal vein occlusion than those initiating other glucose-lowering drugs, suggest results from a South Korean study.

Results from a UK retrospective study suggest that there is “considerable variation” in diabetic eye screening attendance in different age groups, with the worse attendance rates among younger people.

Young people with type 2 diabetes may be predisposed to developing retinal complications, Australian researchers warn.

The incidence of giant cell arteritis is similar among Black and White people, suggests an analysis of a cohort from a US tertiary care center.

The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.

Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

Decreased cytokine concentrations in the aqueous humour are associated with a response to treatment with anti-vascular endothelial growth factor agents in patients with diabetic macular oedema, study data show.

The Port Delivery System with ranibizumab has the potential to reduce the burden of treatment for patients with neovascular age-related macular degeneration, suggest findings from the phase II Ladder trial.

Treatment with faricimab, a bispecific antibody that targets angiopoietin-2 and vascular endothelial growth factor-A, significantly improves visual acuity versus ranibizumab in patients with diabetic macular oedema, research shows.

Measuring CD11b-positive monocytes could help estimate how many anti-vascular endothelial growth factor injections a patient with neovascular age-related macular degeneration or polypoidal choroidal vasculopathy might need, study findings suggest.

Selective laser trabeculoplasty offers superior intraocular pressure stability to that of eye drops and is more cost-effective when used as a first-line treatment for patients with open angle glaucoma or ocular hypertension, results of the LiGHT trial show.

Both triamcinolone acetonide and bevacizumab improve visual acuity when given as an adjunct to cataract surgery in patients with diabetic macular oedema, but only triamcinolone acetonide results in a sustained anatomical improvement, researchers report.

The degree of nerve fibre layer-focal loss volume and the presence of disc haemorrhage may predict the rate of visual field loss in patients with open angle glaucoma, US researchers report.

Biphasic oxygen targets can decrease the incidence and severity of retinopathy of prematuritywithout increasing the risk of death, cohort study findings suggest.

Retinal nerve fibre layer thinning progresses faster in eyes with lamina cribrosa defects than it does in eyes without such defects, shows an analysis of patients enrolled in the Diagnostic Innovations in Glaucoma Study.

Autologous neurosensory retinal transplantation results in the closure of full thickness macular holes in the vast majority of patients for whom previous surgery has failed, study findings indicate.

Progressive choroidal thinning, as measured by swept-source optical coherence tomography “plays a key role” in the evolution of myopic maculopathy in patients with high myopia, say researchers.

Results of the randomised CANTREAT trial add to increasing evidence that a treat-and-extend ranibizumab regimen results in similar visual outcomes, with fewer injections, than monthly treatment for neovascular age-related macular degeneration.